Federal Register: March 25, 2005 (Volume 70, Number 57)
DOCID: FR Doc 05-5922
DEPARTMENT OF DEFENSE
Army Department
NOTICE: NOTICES
ACTION: Patent licenses; non-exclusive, exclusive, or partially exclusive:
DOCUMENT ACTION: Notice.
SUBJECT CATEGORY:
Intent To Grant an Exclusive License of a U.S. Government-Owned Patent
DOCUMENT SUMMARY:
In accordance with 35 U.S.C. 209 and 37 CFR 404.7(a)(1)(i),
announcement is made of the intent to grant an exclusive, royalty
bearing, revocable license within the geographic area of the United
States of America and its territories and possessions to U.S.
Provisional Patent S.N. 60/533,375, filed April 13, 2004 entitled
``Marburg VirusLike Particles as a Vaccine for Prevention of Lethal
Marburg Virus Disease,'' U.S. Patent application 10/289,839, filed
November 7, 2002 entitled ``Generation of Viruslike Particles and
Demonstration of Lipid Rafts as Sites of Filovirus Entry and Budding,''
and U.S. Patent application 10/066,506, filed January 31, 2002
entitled, ``Chimeric Filovirus Glycoprotein,'' for the specific claims
and use related to the viruslike particle technology described
therein, to be limited to the field of use of developing and commercializing prophylactic (preventative) vaccines and
immunotherapties (active and passive) against the Ebola and Marburg
filoviruses, individually or jointly to Virionics Corporation with its
principal place of business at 19108 Barksdale Court, Germantown, MD 208741526.
[[Page 15297]]
SUMMARY:
Virionics, Corp.,
SUPPLEMENTAL INFORMATION
anyone wishing to object to the grant of
this license can file written objections along with supporting
evidence, if any, within 15 days from the date of this publication.
Written objections are to be filed with the Command Judge Advocate,
U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Frederick, MD 217025012.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 055922 Filed 32405; 8:45 am]
BILLING CODE 371008M
FOR FURTHER INFORMATION CONTACT
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 6197808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 6196664, both at telefax (301) 6195034.